Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone and Empagliflozin in Delaying Renal Function Progression in High-Risk CKD Patients After Radical Nephrectomy for Renal Cell Carcinoma
NCT06818305Phase 2Terminated
- Sponsor
- Jinling Hospital
- Start
- Jan 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of finerenone and empagliflozin in chronic kidney disease (CKD) (4 arms), sponsored by Jinling Hospital. Primary endpoint: Incidence of CKD stage 3b (eGFR < 45 mL/min/1.73m²) at 1 year. Started Jan 2025; status: terminated.
02
Drugs
finerenoneempagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06818305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818305.